Skip main navigation

Hurry, only 2 days left to get one year of Unlimited learning for £249.99 £174.99. New subscribers only. T&Cs apply

Find out more

Immunity and Immunogenicity

video

Welcome to week 3. This week, we are going to look at the immunogenicity of biotechnology products. Immunogenicity is defined as the propensity of the therapeutic biologics to elicit immune responses in the form of Anti-Drug Antibodies (ADAs). Immune responses to therapeutic biologics may pose problems for both therapeutic efficacy and patient safety. Both patient-related and product-related factors may affect the immunogenicity of therapeutic biologics. These factors should be taken into consideration in the early stage of therapeutic biologics development.

Initially, immunity and immunogenicity are compared. Then, differences between innate and adaptive immunity are illustrated. Finally, factors that affect immunogenicity, clinical effects of induced antibodies, and strategies to reduce immunogenicity are outlined.

This article is from the free online

Pharmacotherapy: Understanding Biotechnology Products

Created by
FutureLearn - Learning For Life

Reach your personal and professional goals

Unlock access to hundreds of expert online courses and degrees from top universities and educators to gain accredited qualifications and professional CV-building certificates.

Join over 18 million learners to launch, switch or build upon your career, all at your own pace, across a wide range of topic areas.

Start Learning now